Menu
Search
|

Menu

Close
X

Heron Therapeutics Inc HRTX.OQ (NASDAQ Stock Exchange Capital Market)

23.80 USD
-0.10 (-0.42%)
As of Feb 16
chart
Previous Close 23.90
Open 23.80
Volume 130,765
3m Avg Volume 207,959
Today’s High 24.40
Today’s Low 23.60
52 Week High 24.75
52 Week Low 12.70
Shares Outstanding (mil) 54.50
Market Capitalization (mil) 1,297.21
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.58 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
21
FY16
1
FY15
0
EPS (USD)
FY17
-2.564
FY16
-4.551
FY15
-2.945
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
58.98
8.57
Price to Book (MRQ)
vs sector
32.39
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
71.11
15.12
LT Debt to Equity (MRQ)
vs sector
62.42
11.85
Return on Investment (TTM)
vs sector
-275.26
13.54
Return on Equity (TTM)
vs sector
-631.62
14.80

EXECUTIVE LEADERSHIP

Kevin Tang
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Robert Rosen
President, Director, Since 2013
Salary: $579,143.00
Bonus: --
Barry Quart
Chief Executive Officer, Director, Since 2017
Salary: $579,143.00
Bonus: --
Robert Hoffman
Chief Financial Officer, Senior Vice President - Finance, Since 2017
Salary: --
Bonus: --
Kimberly Manhard
Executive Vice President - Drug Development, Since 2016
Salary: $401,077.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4242 Campus Point Ct Ste 200
SAN DIEGO   CA   92121-1513

Phone: +1650.3662626

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

SPONSORED STORIES